Summary
Can-Fite BioPharma Ltd (Can-Fite) is a biopharmaceutical company that offers pharmaceutical discovery and clinical development services. The company's pipeline product portfolio includes CF101, CF102 and CF602. It develops its products by utilizing its platform technology based on the Gi protein coupled A3 adenosine receptor (A3AR) in inflammatory and cancer cells. Can-Fite developes drugs that are used in the treatment of various diseases such as cancer, sexual dysfunction, inflammatory diseases and ophthalmic indications. The company’s CF 102, is an oral drug used to treat liver cancer and CF 602, is an allosteric modulator used in the treatment of inflammatory diseases. It conducts Phase I, II and III clinical trials for various indications across the US and Israel. Can-Fite is headquartered in Petah-Tikva, Israel.
Can-Fite BioPharma Ltd (CANF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 12
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 12
Merger 13
OphthaliX to Merge with Wize Pharma 13
Licensing Agreements 14
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 14
Equity Offering 15
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 15
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 16
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 17
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 18
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 19
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 21
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 22
OphthaliX Files Registration Statement For Public Offering Of Shares For US$10 Million 23
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 23
Denali Concrete Completes Private Placement Of Shares For Above US$6 Million 25
Acquisition 25
Denali Concrete Acquires EyeFite From Can-Fite BioPharma 25
Can-Fite BioPharma Ltd - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
May 30, 2017: Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update 30
Mar 31, 2017: Can-Fite Reports 2016 Financial Results & Provides Clinical Update 32
Nov 25, 2016: Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update 34
Aug 26, 2016: Can-Fite Reports Financial Results for Six Months Ended June 30, 2016 36
May 27, 2016: Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update 38
Apr 01, 2016: Can-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update 40
Research And Development 42
Jun 05, 2017: Can-Fite BioPharma establishes clinical advisory board for NAFLD and NASH treatment 42
Product News 43
Aug 08, 2016: Can-Fites Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology 43
Jan 11, 2016: Can-Fite Announces Update on CF101 44
Jan 11, 2016: Can-Fite Announces Update on CF102 45
Clinical Trials 46
Oct 13, 2016: Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH 46
Sep 13, 2016: Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial 47
Jul 25, 2016: Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD 48
Jul 05, 2016: OphthaliX Announces Phase II Glaucoma Data 49
Jun 15, 2016: Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects 50
Jun 07, 2016: Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) 51
Jun 01, 2016: Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis 52
Mar 17, 2016: Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis 53
Jan 05, 2016: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 12
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 12
OphthaliX to Merge with Wize Pharma 13
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 14
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 15
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 16
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 17
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 18
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 19
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 21
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 22
OphthaliX Files Registration Statement For Public Offering Of Shares For US$10 Million 23
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 23
Denali Concrete Completes Private Placement Of Shares For Above US$6 Million 25
Denali Concrete Acquires EyeFite From Can-Fite BioPharma 25
Can-Fite BioPharma Ltd, Key Competitors 27
Can-Fite BioPharma Ltd, Key Employees 28
Can-Fite BioPharma Ltd, Other Locations 29
Can-Fite BioPharma Ltd, Subsidiaries 29List of Figures
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
